Eva Leander

Title: Eva Leander: Innovator in Pharmaceutical Chemistry

Introduction

Eva Leander is a prominent inventor based in Skiptvet, Norway. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds and processes. With a total of 2 patents to her name, her work has the potential to impact the pharmaceutical industry significantly.

Latest Patents

Eva Leander's latest patents include a novel process for the preparation of the magnesium salt of the (−)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1-benzimidazole trihydrate, known as S-omeprazole magnesium salt trihydrate. This invention not only details the preparation process but also includes pharmaceutical compositions containing this compound. Additionally, she has developed a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate, along with processes for its preparation and related pharmaceutical compositions.

Career Highlights

Eva Leander is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. Her work at AstraZeneca has allowed her to focus on innovative solutions in drug development, contributing to the advancement of therapeutic options for various medical conditions.

Collaborations

Eva has collaborated with notable colleagues, including Anders Kronström and Anders Mattson. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Eva Leander's contributions to pharmaceutical chemistry through her innovative patents and collaborations highlight her role as a key inventor in the industry. Her work continues to pave the way for advancements in drug formulation and therapeutic applications.